Novel anti-cancer vaccines based on oral application of recombinant Salmonella typhimurium bacteria

Number of publications: 4
Israeli Partner: R. Apte, Ben Gurion University
German Partner: M. Zoeller, DKFZ


Dvorkin, T., Song, X., Argov, S., White, R. M., Zoller, M., Segal, S., Dinarello, C. A., Voronov, E., Apte, R. N.

Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha 80 (1), J Leukoc Biol, 96-106, 2006

Hummel, S., Apte, R. N., Qimron, U., Vitacolonna, M., Porgador, A., Zoller, M.

Tumor vaccination by Salmonella typhimurium after transformation with a eukaryotic expression vector in mice: impact of a Salmonella typhimurium gene interfering with MHC class I presentation 28 (5), J Immunother, 467-79, 2005

Zoller, M.

Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option? 53 (8), Cancer Immunol Immunother, 659-76, 2004

Zoller, M.

Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host 171 (12), J Immunol, 6941-53, 2003

to top